AbbVie Lifts Outlook After Arthritis Drugs Boost 3Q Sales

AbbVie bumped earnings guidance higher following strong third-quarter sales as gains from the company's newer anti-inflammatory drugs offset expected declines ...

AbbVie bumped earnings guidance higher following strong third-quarter sales as gains from the company's newer anti-inflammatory drugs offset ...

AbbVie raises 2024 profit forecast on strong sales of key drugs ...

AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat ...

AbbVie's Skyrizi snatches sales crown from Humira as company lifts ...

It's a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly ...

AbbVie Lifts Profit Outlook as Inflammatory Drugs Rinvoq and Skyrizi ...

AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, ...

Rinvoq, Skyrizi lift Abbvie 3Q 2024 profits | Crain's Chicago Business

... sales of Humira, its former flagship treatment for inflammatory diseases such as arthritis ... Abbvie lifts profit outlook as inflammatory drugs ...

AbbVie raises profit forecast as CEO cites business "momentum"

... after third-quarter net revenue topped estimates ... medications since its blockbuster arthritis drug Humira lost patent protection last year.

AbbVie lifts profit outlook as inflammatory drugs beat estimates

... sales of Humira, its former flagship treatment for inflammatory diseases such as arthritis. ... sales topped $3.21 billion in the third quarter ...

AbbVie Reports Third-Quarter 2024 Financial Results

Global Rinvoq net revenues were $1.614 billion, an increase of 45.3 percent on a reported basis, or 47.4 percent on an operational basis. Global ...

AbbVie Raises Full-Year Outlook Following Third-Quarter Beat

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, ...

AbbVie raises 2024 profit forecast on strong sales of key drugs ...

Oct 30 (Reuters) – AbbVie (ABBV.N) raised its annual profit forecast on Wednesday after strong sales of its newer immunology drugs and key ...

AbbVie raises 2027 sales forecast for new immunology drugs to $27 ...

AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and Rinvoq to $27 billion, up $6 billion from its ...

AbbVie Lifts Profit Outlook as Newer Biologics Help Buffer Dwindling ...

AbbVie Inc. raised its profit outlook for this year and next as demand for newer biologic drugs helped fill the gap left by falling Humira sales.

AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for ...

AbbVie on Friday beat Wall Street expectations in its first quarter of 2024, thanks in part to robust sales of its immunology drugs Rinvoq and Skyrizi.

ABBV - AbbVie Inc News - Morningstar

AbbVie Lifts Outlook After Arthritis Drugs Boost 3Q Sales. Global News Select Oct 30, 2024 5:31am. AbbVie Raises Quarterly Dividend by 5.8% to $1.64/Share.

Press Release | AbbVie Investor Relations

Third-quarter global IMBRUVICA net revenues were $688 million, with U.S. sales of $574 million and international profit sharing of $114 million for the quarter, ...

AbbVie Sees Signs of Post-Humira Growth in Positive 2024 Outlook

Both drugs beat Wall Street's estimates in the fourth quarter and AbbVie lifted its combined 2027 sales outlook for the duo to $27 billion, up ...

AbbVie results beat expectations despite low-cost competition to ...

on Friday reported third-quarter sales and profit that topped analyst expectations and raised its full-year earnings outlook, even as its ...

AbbVie expects Skyrizi, Rinvoq to eclipse Humira's sales peak, CEO ...

In its last third quarter of true market supremacy, Humira carried its weight in the U.S., lifting sales 7.4% to $4.96 billion. The drug fared ...

AbbVie Reports Higher Sales, Outlook - WSJ

Drug Maker Sees Benefits From Arthritis Drug Humira Now, Hepatitis C Treatment Later ... AbbVie Inc. boosted its earnings guidance for the year ...